Table 3.
Diagnostic accuracy of PET/CT parameters to discriminate between complete response and non-complete response groups of patients with relapsed/refractory diffuse large B-cell lymphoma (n = 55) after two cycles and the last cycle of treatment with bendamustine–rituximab
| Threshold, % | AUC | P-value | Sensitivity, % | Specificity, % | |
|---|---|---|---|---|---|
| Baseline – two cycles | |||||
| ΔSUV02 | 66.0 | 0.770 | 0.0230 | 80.0 | 60.0 |
| ΔSUL02 | 65.0 | 0.700 | 0.0300 | 80.0 | 60.0 |
| ΔMTV02 | 68.0 | 0.776 | 0.0400 | 73.3 | 62.0 |
| ΔΣMTV02 | 66.0 | 0.867 | 0.0490 | 73.3 | 60.0 |
| ΔTLG02 | 68.0 | 0.784 | 0.0300 | 74.6 | 63.8 |
| ΔΣTLG02 | 67.0 | 0.875 | 0.0470 | 80.0 | 65.0 |
| ΔAUC-CSH02 | −3.7 | 0.419 | 0.3590 | 53.3 | 55.0 |
| Baseline – last cycle | |||||
| ΔSUV0L | 75.0 | 0.728 | 0.0010 | 73.8 | 67.8 |
| ΔSUL0L | 70.0 | 0.697 | 0.0140 | 72.7 | 66.7 |
| ΔMTV0L | 65.0 | 0.758 | 0.0010 | 80.1 | 69.7 |
| ΔΣMTV0L | 61.0 | 0.865 | 0.0010 | 77.3 | 75.8 |
| ΔTLG0L | 67.0 | 0.765 | 0.0010 | 77.3 | 75.8 |
| ΔΣTLG0L | 66.0 | 0.878 | <0.0001 | 81.8 | 75.8 |
| ΔAUC-CSH0L | −6.0 | 0.591 | 0.2570 | 63.6 | 54.5 |
AUC, area under the curve; Δ, percentage change; 02, from baseline to after 2 cycle; 0L, from baseline to after last cycle; SUV, maximum standardized uptake value; SUL, standardized uptake value corrected by lean body mass; MTV, metabolic tumor volume; ΣMTV, sum of MTV for a maximum of 6 target lesions per patient; TLG, total lesion glycolysis; ΣTLG, sum of TLG for a maximum of 6 target lesions per patient; AUC-CSH, area under the curve of cumulative SUV-volume histogram.